Company intelligence / Profile preview

MediciNova, Inc.

La Jolla, California, United Statesmedicinova.com ↗

Ownership: Public · MNOV
Employees: ~13
Development stage: Phase 3

Overview

MediciNova is developing multiple drug candidates with MN-166 (ibudilast) in Phase 2b/3 clinical trials for neurological disorders and MN-001 (tipelukast) in Phase 2 for fibrotic and metabolic disorders. Recent positive results were reported for MN-166 in glioblastoma trials and for preventing ARDS.

Therapeutic areas: GastroenterologyPulmonologyPsychiatryOncologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

12 assets

ibudilast

11 more assets in the full pipeline.

Request access →

Partnerships

Kyorin Pharmaceutical Co., Ltd.Kissei Pharmaceutical Co., Ltd.

Financials

Market cap: $85.6M
Total revenue: $458.4K
Enterprise value: $60.3M

Beyond the preview

Go deeper on MediciNova, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MediciNova, Inc..

Explore the full profile